Half matched transplant in sickle cell anaemia

Establishing a platform for Haplo-identical transplant in Children with Sickle cell disease (HaChS study) - HaChS

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/09/021274

Enrollment

Registered

2019-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs

Interventions

Intervention1: Haploidentical Transplant conditioning regimen: Fludarabine 40 mg/m2/day x 4 days [Days -5 to -2] Thiotepa 8 mg/Kg IV on Day - 6 Treosulfan 14 G/m2/day x 3 days [Days â?? 5 to -3] Thy

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed to have Sickle cell disease 2.Should have failed hydroxyurea or unwilling to take Hydroxyurea 3.Adequate cardiac, hepatic and renal function 4.Absence of matched sibling or a matched unrelated donor

Exclusion criteria

Exclusion criteria: 1.Multiple strokes with residual paraparesis 2.Poor cardiac, hepatic or renal functions [ > 4 times ULN]

Design outcomes

Primary

Measure	Time frame
To study the 1 year overall survival in patients undergoing haplo-identical transplantation for Sickle cell disease using a Treosulfan based regimenTimepoint: 12 months	—

Secondary

Measure	Time frame
1.To study the incidence of acute and chronic graft versus host disease in patients undergoing Haplo-identical HSCT. 2.To study the pattern of immune reconstitution following Haplo-identical HSCT. 3.To study the risk of infectious complications following Haplo-identical HSCT. 4.To study the incidence of primary and secondary graft failure following Haplo-identical HSCT.Timepoint: Day 30, 60, 90, 180 and 360	—

Measure

Time frame

1.To study the incidence of acute and chronic graft versus host disease in patients undergoing Haplo-identical HSCT. 2.To study the pattern of immune reconstitution following Haplo-identical HSCT. 3.To study the risk of infectious complications following Haplo-identical HSCT. 4.To study the incidence of primary and secondary graft failure following Haplo-identical HSCT.Timepoint: Day 30, 60, 90, 180 and 360

—

Countries

India

Contacts

Public ContactBiju George

Christian Medical College, Vellore

biju@cmcvellore.ac.in04162282352

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026